Where to buy BPC-157.

A 2026 sourcing guide for BPC-157 — the pentadecapeptide with the largest preclinical literature in research peptides, the 2023 FDA 503A Category 2 designation, and the specific identity verification questions every research buyer should ask.

Buying guide8 min read

Key takeaway

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide originally isolated from human gastric juice. Look for CAS number 137525-51-0 and molecular weight 1419.6 g/mol on the CoA. It’s legal to buy as research material, but the FDA flagged it as 503A Category 2 in 2023, which closes the compounding-pharmacy channel for human use. On November 17, 2026, US research suppliers listed 5 mg vials at $39.99–$60.00 and 10 mg vials at $25.00–$97.00. The two red flags: vendors selling “Plus” or “Stable” variants without disclosing structural changes, and vendors making clinical claims like “heals tendons in 4 weeks.”

At a glance

Article typeBuying guide
Main guideBPC-157: complete guide
Regulatory statusNot FDA-approved“It's not an FDA-approved drug” (BPC-157: complete guide)
ClassTissue repair
Body systemsSkin & connective tissue, Gut, Muscle & bone, Heart & vessels
Studies cited5 in this article · 27 across 14 articles on BPC-157
ProductBPC-157 product page

BPC-157 has the largest preclinical literature of any research peptide in tissue repair: 35 rodent studies, 1 uncontrolled human case series, and zero controlled human trials as of 2026. Buying it is simple once you know what to ask. Where to buy BPC-157 in 2026 comes down to three checks: is the Certificate of Analysis (CoA) from a third-party lab, does the mass match, and is it the standard 15-amino-acid peptide rather than an undisclosed variant?

Get new research first

Research updates
Citation-anchored summaries New-batch COA alerts Unsubscribe anytime

One short email when new peptide research drops or a new lab-verified batch lands — written from primary sources, no filler.

Quick answer: On November 17, 2026, US research suppliers listed lyophilized (freeze-dried) BPC-157 at $25.00–$97.00 per vial. Demand a CoA from an ISO 17025 lab (an internationally recognized testing standard) showing HPLC purity above 98%, mass-spec at 1420.6, and water under 8%. Stick with the standard pentadecapeptide. Skip the “Plus” or “Advanced” variants.

What you’re actually buying

BPC-157 is a chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The name “Body Protection Compound” comes from how it was discovered: as a partial sequence inside a larger protein found in human gastric juice.

A 2025 review describes BPC-157 as showing diverse effects across animal models — tissue injury, gut inflammation, brain injury — though the studies remain almost entirely preclinical (Jozwiak et al., 2025).

One unusual property: BPC-157 stays stable in stomach acid for over 24 hours (Sikiric et al., 2022). That stability is why some vendors market “Stable BPC-157” variants. But the standard peptide is already stable. “Improved” variants without published structures are marketing language, not chemistry.

Three buyer checks for BPC-157

The general eight criteria for any peptide vendor apply. Three matter more for BPC-157:

1. The CAS number on the CoA must be 137525-51-0

CAS Registry Numbers are unique chemical IDs that never change. BPC-157’s is 137525-51-0. A credible CoA lists it on the identity line. Cross-check it against PubChem or ChemSpider in 30 seconds. A missing CAS, or one that doesn’t resolve to BPC-157, is a critical gap.

2. The mass-spec result must match 1420.6

BPC-157’s theoretical mass is 1419.6 g/mol. Mass-spec on the CoA should show observed mass at [M+H]+ 1420.6 (or [M−H]− 1418.6 in negative mode), within 0.5 Da of theoretical. An observed mass meaningfully different means the vial contains either a different molecule or a partially synthesized fragment. The mass match is your single most direct identity check.

3. The form should be lyophilized injectable

BPC-157 ships as a lyophilized (freeze-dried) powder, the form used across the published preclinical literature. Reconstitution with bacteriostatic water prior to in-vitro or in-vivo research use is standard laboratory practice. Some vendors sell pre-mixed liquid, oral capsules, or sublingual sprays. Pre-mixed liquid has a much shorter stability window — weeks instead of years. Oral and sublingual forms have not been validated in any controlled study. Research matching the published literature requires the lyophilized powder.

Where this falls short: The published BPC-157 literature is huge but lopsided. Roughly 75% of preclinical studies come from one research group in Zagreb. The 35-plus rodent studies haven’t been replicated by independent labs at scale. The single human study is a 17-patient uncontrolled case series. The FDA flagged BPC-157 as a safety question in 2023 precisely because the human data is too thin to support compounded human use. Buy it as a research tool. Don’t buy it as a proven therapeutic.

BPC-157

Pentadecapeptide 15 aa Gastric origin

The standard pentadecapeptide cited across the 2025 multifunctionality review and the 2025 HSS Journal systematic review. CAS 137525-51-0, observed mass [M+H]+ 1420.6, ≥99% HPLC purity, third-party CoA on every lot.

View BPC-157

2026 pricing benchmarks

BPC-157 is one of the cheaper research peptides to make — only 15 residues, no chemical modifications, well-established synthesis route. We checked US research supplier product pages on November 17, 2026. Listed single-vial prices, before shipping and codes:

  • 5 mg vial: $39.99–$60.00 ($8.00–$12.00 per mg).
  • 10 mg vial: $25.00–$97.00 ($2.50–$9.70 per mg). Better per-mg value than the 5 mg.
  • Multi-vial tiers: several suppliers list volume discounts of 5% to 20%.

The full table, with each supplier and source, is on our BPC-157 price page.

A price far below the rest of the market deserves a question. The HPLC purification step is what separates “crude BPC-157” (right sequence, contaminated with synthesis byproducts) from “research-grade BPC-157” (purified above 98%). The cheap end of the market usually skips that step. Far above the range, you’re paying retail markup, not synthesis cost.

What does 503A Category 2 actually mean?

In February 2023, the FDA reviewed BPC-157 and put it in 503A Category 2 — the “may present significant safety risks” bucket. Section 503A is the part of federal law that governs compounding pharmacies (the kind that make custom medications a doctor prescribes).

The 2023 decision was widely covered as a “ban.” That’s partly true and partly misleading.

What the designation does:

  • Closes compounding pharmacies as a human-use channel. Pharmacies can’t include BPC-157 in compounded prescriptions anymore. That shut down a small but visible path BPC-157 had been reaching human users through.
  • Signals FDA concern about the human-safety evidence. The decision reflects the agency’s view that human data is too thin.

What the designation does not do:

  • It doesn’t stop research-grade sales. Research-use-only suppliers operate under a different regulation entirely (21 CFR § 809.10(b)(9)).
  • It doesn’t make laboratory research illegal. Animal studies and in-vitro work continue.
  • It doesn’t ban formal clinical trials. Pharmaceutical-grade BPC-157 can still be tested in an FDA-approved trial under standard IND (investigational new drug) procedures.

For more detail, see our article on peptides and the 2023 503A categorization.

Red flags specific to BPC-157

Seven warning signs we’d skip:

  • “BPC-157 Plus,” “Advanced,” “Stable,” or “Arg” variants. Marketing names without disclosed structural changes. The standard peptide is already gastric-stable; “improved” without a published structure is marketing.
  • Pre-mixed liquid shipped without cold chain. The powder survives shipping. Liquid at room temperature degrades fast.
  • Capsules, sublingual sprays, or patches. No controlled study has validated any of these. The injectable powder is what the published research uses.
  • Clinical claims on the product page. “Treats joint pain.” “Heals tendons in 4 weeks.” A vendor making clinical claims about a 503A Category 2 substance is in FDA enforcement territory.
  • Missing CAS number on the CoA. CAS 137525-51-0 is the molecule’s ID. Its absence is a red flag.
  • Mass-spec result not at 1420.6. If the mass is wrong, the molecule is wrong.
  • Vendor’s own QC instead of third-party testing. Internal QC is fine for raw material. Independent ISO 17025 testing is the standard for research-grade.
Figure 1

BPC-157 published evidence by tier.

The published BPC-157 literature is large in volume but heavily preclinical. Researchers should match their evidence-tier expectations to the actual published basis — mouse and rat models dominate; controlled human RCTs do not yet exist.

0 papers 10 25 40+ papers In-vitro studies Dozens — cell-line and tissue work Rodent models 35+ studies, multiple injury types Other animal models Small number, mostly Zagreb lab Human case series 1 (Lee & Padgett, 17 patients, uncontrolled) Controlled human RCTs 0 published Authorship concentration ~75% of preclinical work from one Zagreb group Systematic reviews (2025+) 2 (HSS Journal, Pharmaceuticals)

Source: aggregate counts from the 2025 HSS Journal systematic review (Vasireddi et al., 2025), 2025 Pharmaceuticals literature review (Józwiak et al., 2025), and PubMed retrievals 2010–2026.

BPC-157

10 mg ≥99% pure Lyophilized

Standard pentadecapeptide, CAS 137525-51-0. The same reference compound used across the 35+ preclinical studies aggregated in the 2025 HSS Journal systematic review. COA with HPLC trace and mass-spec ships with every order.

Learn more

Frequently asked questions

Is BPC-157 legal to buy in the USA?

Yes, as a research reference compound. The 2023 FDA 503A Category 2 designation closed the compounding-pharmacy channel for human use. It didn’t affect research-grade sales. Buying as research material is legal. Selling with human-use claims isn’t.

How much should research-grade BPC-157 cost?

On November 17, 2026, US research suppliers listed 5 mg vials at $39.99–$60.00 and 10 mg vials at $25.00–$97.00 ($2.50–$12.00 per mg). Far below that range, purity is usually the trade-off. Far above it, you’re paying retail markup, not synthesis cost. Our BPC-157 price page has the full table.

What should a BPC-157 CoA show?

Five things: CAS 137525-51-0 on the identity line, HPLC purity above 98% with the chromatogram attached, mass-spec at observed [M+H]+ 1420.6, water content (Karl Fischer titration) of 2–8%, and counterion content (usually trifluoroacetate at 5–15% by mass). The testing lab should be ISO 17025-accredited and named on the report.

What does 503A Category 2 mean for buyers?

Compounding pharmacies can’t prepare BPC-157 for human use anymore. That’s it. Research-grade sales operate under a different regulation and aren’t affected. Only the compounding-pharmacy channel changed.

What are “BPC-157 Plus” or “Advanced” variants?

Marketing names. Vendors claim improved stability or bioavailability but don’t publish the structural modification or peer-reviewed evidence. These products aren’t the BPC-157 in the literature. If you’re matching published research, buy the standard pentadecapeptide.

How does BPC-157 compare to TB-500?

Different mechanisms. BPC-157 acts through growth-factor pathways and angiogenesis. TB-500 acts through actin and cell migration. Preclinical studies have investigated the two compounds together, noting that their pharmacological mechanisms are largely non-overlapping. See the BPC-157 vs TB-500 comparison.

What to know now

  • CAS 137525-51-0, MW 1419.6, observed [M+H]+ 1420.6. The numbers a credible CoA shows.
  • $25.00–$97.00 per vial on November 17, 2026, depending on size and supplier. 15 residues with no modifications keeps synthesis cheap.
  • 503A Category 2 closed compounding pharmacies, not research suppliers. Research sales continue unchanged.
  • Standard pentadecapeptide only. “Plus,” “Stable,” or “Advanced” without published structures aren’t BPC-157.
  • Lyophilized injectable is the literature form. Capsules and sprays aren’t validated.
  • Preclinical-heavy evidence. 35+ rodent studies, 1 uncontrolled case series, zero RCTs.

What we’re watching

The big development to track: whether a controlled human trial — randomized, blinded, real outcome measures — ever publishes. Twenty years into the literature, the human evidence is one 17-patient case series. Both the 2025 HSS Journal review and the 2026 Sports Medicine review explicitly call for proper clinical investigation. Until those trials run, BPC-157 stays a mechanistically interesting research compound where the preclinical signal outpaces the human data. We’re also watching the FDA 503A category review for any change to the BPC-157 designation — the list is reviewed periodically.

Also in the library

More for skin & connective tissue

All 23 compounds for skin & connective tissue

Sources: Józwiak 2025, Pharmaceuticals; Vasireddi 2025, HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery; Sikiric 2022, World Journal of Gastroenterology; Mendias 2026, Sports Medicine; Lee 2021, Altern Ther Health Med; U.S. Food and Drug Administration 2023, Section 503A of the Federal Food, Drug, and Cosmetic Act; International Organization for Standardization 2017. All 7 citations

Back to the research library

References

  1. Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
  2. Vasireddi, N., Vasireddi, N., Shankar, D. S., Mojica, E. S., Boylan, M. R., Aitcheson, J. C., Wilson, A., Strauss, E. J., Alaia, M. J., & Campbell, K. A. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery. https://doi.org/10.1177/15563316251355551
  3. Sikiric, P., Skrtic, A., Gojkovic, S., Krezic, I., Zizek, H., Lovric, E., Sikiric, S., Pavlov, K. H., Rucman, R., Boban Blagaic, A., Brcic, L., & Strbe, S. (2022). Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World Journal of Gastroenterology, 28(1), 23–46. https://doi.org/10.3748/wjg.v28.i1.23
  4. Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0
  5. Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. PMID 34324435
  6. U.S. Food and Drug Administration. (2023). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
  7. International Organization for Standardization. (2017). ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html